PE20151060A1 - Nuevos derivados de pirazina como agonistas del receptor cb2 - Google Patents
Nuevos derivados de pirazina como agonistas del receptor cb2Info
- Publication number
- PE20151060A1 PE20151060A1 PE2015000736A PE2015000736A PE20151060A1 PE 20151060 A1 PE20151060 A1 PE 20151060A1 PE 2015000736 A PE2015000736 A PE 2015000736A PE 2015000736 A PE2015000736 A PE 2015000736A PE 20151060 A1 PE20151060 A1 PE 20151060A1
- Authority
- PE
- Peru
- Prior art keywords
- agonists
- receptor
- new
- pirazine
- cyclopropylmetoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN DERIVADO DE PIRAZINA DE FORMULA (I) DONDE R1 ES CICLOALQUILALCOXI O HALOALCOXI; R2 ES CICLOALQUILO O HALOAZETIDINILO; R3 Y R4 SON CADA UNO ALQUILO, ALCOXI, ALCOXIALQUILO, O R3 Y R4 JUNTO CON EL ATOMO DE N AL QUE ESTAN UNIDOS FORMAN UN HETEROCICLILO OPCIONALMENTE SUSTITUIDO TAL COMO MORFOLINILO, OXOMORFOLINILO, 2-OXO-5-AZA-BICICLO[2.2.1]HEPTILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5-CICLOPROPIL-6-CICLOPROPILMETOXI-PIRAZIN-2-IL)-((R)-2-METIL-PIRROLIDIN-1-IL)-METANONA; [6-CICLOPROPILMETOXI-5-(3,3-DIFLUOR-AZETIDIN-1-IL)-PIRAZIN-2-IL]-((R)-2-METIL-PIRROLIDIN-1-IL)-METANONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE CANABINOIDES 2 SIENDO UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, RETINOPATIA DIABETICA, GLAUCOMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196024 | 2012-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151060A1 true PE20151060A1 (es) | 2015-07-25 |
Family
ID=47290805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000736A PE20151060A1 (es) | 2012-12-07 | 2013-12-04 | Nuevos derivados de pirazina como agonistas del receptor cb2 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9512141B2 (es) |
| EP (1) | EP2928882B1 (es) |
| JP (1) | JP6322646B2 (es) |
| KR (1) | KR20150092156A (es) |
| CN (1) | CN104837830B (es) |
| AR (1) | AR093804A1 (es) |
| AU (1) | AU2013354115B2 (es) |
| BR (1) | BR112015009603A2 (es) |
| CA (1) | CA2885418A1 (es) |
| CL (1) | CL2015001318A1 (es) |
| CR (1) | CR20150210A (es) |
| CY (1) | CY1118808T1 (es) |
| DK (1) | DK2928882T3 (es) |
| EA (1) | EA025840B1 (es) |
| ES (1) | ES2621958T3 (es) |
| HR (1) | HRP20170572T1 (es) |
| HU (1) | HUE030836T2 (es) |
| IL (1) | IL237982A (es) |
| IN (1) | IN2015DN03145A (es) |
| LT (1) | LT2928882T (es) |
| MA (1) | MA38217B1 (es) |
| MX (1) | MX2015006036A (es) |
| PE (1) | PE20151060A1 (es) |
| PH (1) | PH12015501072A1 (es) |
| PL (1) | PL2928882T3 (es) |
| PT (1) | PT2928882T (es) |
| RS (1) | RS55951B1 (es) |
| SG (1) | SG11201504011UA (es) |
| SI (1) | SI2928882T1 (es) |
| TW (1) | TW201427960A (es) |
| UA (1) | UA116894C2 (es) |
| WO (1) | WO2014086807A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS56148B1 (sr) | 2013-03-07 | 2017-11-30 | Hoffmann La Roche | Novi derivati pirazola |
| RS56927B1 (sr) | 2013-03-26 | 2018-05-31 | Hoffmann La Roche | Novi derivati piridina |
| ES2635632T3 (es) | 2013-05-02 | 2017-10-04 | F. Hoffmann-La Roche Ag | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor CB2 |
| MX376599B (es) | 2013-05-02 | 2025-03-07 | Hoffmann La Roche | Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2). |
| PE20191528A1 (es) | 2013-09-06 | 2019-10-23 | Hoffmann La Roche | Nuevos derivados de triazolo[4,5-d]pirimidina |
| PE20161370A1 (es) * | 2014-04-04 | 2016-12-17 | Hoffmann La Roche | Nuevos derivados de piridina utiles como antagonistas de cb2 |
| MX376414B (es) | 2015-12-09 | 2025-03-07 | Hoffmann La Roche | Derivados de fenilo como agonistas del receptor de canabinoides 2. |
| CN110753690B (zh) | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| EP3814329B1 (en) | 2018-06-27 | 2024-01-17 | F. Hoffmann-La Roche AG | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814337B1 (en) | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| BRPI0717822A2 (pt) * | 2006-10-04 | 2013-11-12 | Hoffmann La Roche | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
-
2013
- 2013-12-04 PE PE2015000736A patent/PE20151060A1/es not_active Application Discontinuation
- 2013-12-04 US US14/648,399 patent/US9512141B2/en not_active Expired - Fee Related
- 2013-12-04 MX MX2015006036A patent/MX2015006036A/es unknown
- 2013-12-04 SG SG11201504011UA patent/SG11201504011UA/en unknown
- 2013-12-04 CN CN201380063228.9A patent/CN104837830B/zh not_active Expired - Fee Related
- 2013-12-04 LT LTEP13799545.2T patent/LT2928882T/lt unknown
- 2013-12-04 RS RS20170313A patent/RS55951B1/sr unknown
- 2013-12-04 EP EP13799545.2A patent/EP2928882B1/en not_active Not-in-force
- 2013-12-04 BR BR112015009603A patent/BR112015009603A2/pt not_active Application Discontinuation
- 2013-12-04 UA UAA201506212A patent/UA116894C2/uk unknown
- 2013-12-04 AU AU2013354115A patent/AU2013354115B2/en not_active Ceased
- 2013-12-04 ES ES13799545.2T patent/ES2621958T3/es active Active
- 2013-12-04 MA MA38217A patent/MA38217B1/fr unknown
- 2013-12-04 PT PT137995452T patent/PT2928882T/pt unknown
- 2013-12-04 EA EA201590827A patent/EA025840B1/ru not_active IP Right Cessation
- 2013-12-04 IN IN3145DEN2015 patent/IN2015DN03145A/en unknown
- 2013-12-04 KR KR1020157014961A patent/KR20150092156A/ko not_active Withdrawn
- 2013-12-04 JP JP2015545985A patent/JP6322646B2/ja active Active
- 2013-12-04 CA CA2885418A patent/CA2885418A1/en not_active Abandoned
- 2013-12-04 SI SI201330591A patent/SI2928882T1/sl unknown
- 2013-12-04 WO PCT/EP2013/075444 patent/WO2014086807A1/en active Application Filing
- 2013-12-04 DK DK13799545.2T patent/DK2928882T3/en active
- 2013-12-04 PL PL13799545T patent/PL2928882T3/pl unknown
- 2013-12-04 HR HRP20170572TT patent/HRP20170572T1/hr unknown
- 2013-12-04 HU HUE13799545A patent/HUE030836T2/en unknown
- 2013-12-05 AR ARP130104504A patent/AR093804A1/es unknown
- 2013-12-06 TW TW102144989A patent/TW201427960A/zh unknown
-
2015
- 2015-03-26 IL IL237982A patent/IL237982A/en not_active IP Right Cessation
- 2015-04-22 CR CR20150210A patent/CR20150210A/es unknown
- 2015-05-14 PH PH12015501072A patent/PH12015501072A1/en unknown
- 2015-05-15 CL CL2015001318A patent/CL2015001318A1/es unknown
-
2017
- 2017-04-07 CY CY20171100418T patent/CY1118808T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
| PE20150684A1 (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
| PE20150352A1 (es) | Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona | |
| PE20110328A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
| CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| PE20141578A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 | |
| PE20160664A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| UA116467C2 (uk) | Модулятори p2x7 | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20160839A1 (es) | Derivados de 4-azaindol | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| PE20160691A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
| PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
| PE20151559A1 (es) | Nuevos derivados de piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |